Core Insights - Aspo Plc has published its Annual Review for 2025, which includes the Board of Directors' Report and Financial Statements, available in both English and Finnish [1] Financial Reporting - The Consolidated Financial Statements are published in accordance with the European Single Electronic Format (ESEF) reporting requirements, with primary statements and notes labeled with XBRL tags [3] - Deloitte Oy has provided an independent auditor's reasonable assurance report on Aspo's ESEF financial statements in accordance with ISAE 3000 [3] Sustainability and Governance - Aspo's Sustainability Statement, part of the Board of Directors' Report, is based on the EU Corporate Sustainability Reporting Directive (CSRD) and has been assured by Deloitte Oy at a limited assurance level [2] - The company has also published its Corporate Governance Statement and Remuneration Report for 2025, which are available on its website [4] Company Overview - Aspo creates value by owning and developing business operations sustainably and in the long term, with a focus on ESL Shipping and Telko, providing sustainable choices for customers across various industries [4] - Established in 1929, Aspo operates with approximately 650 experts and serves customers in 18 countries across Europe and parts of Asia, with the Nordic region as its core market [4][5]

Core Viewpoint - Municipality Finance Plc has issued a new tranche of GBP 70 million under its MTN programme, increasing the total benchmark amount to GBP 400 million, with a fixed interest rate of 4.250% per annum and a maturity date of 9 January 2029 [1]. Group 1: Issuance Details - The new tranche is part of MuniFin's EUR 50 billion programme for debt instruments [2]. - The public trading of the new tranche is expected to commence on 25 March 2026 on the Helsinki Stock Exchange [3]. - Nomura International plc is acting as the Dealer for this issuance [3]. Group 2: Company Overview - MuniFin is one of Finland's largest credit institutions, with a balance sheet exceeding EUR 55 billion [4]. - The company is owned by Finnish municipalities, the public sector pension fund Keva, and the State of Finland [4]. - MuniFin focuses on environmentally and socially responsible investments, serving various public sector entities [5]. Group 3: Market Position - MuniFin operates in a global business environment and is a prominent issuer in international capital markets, being the first Finnish issuer of green and social bonds [6].

Core Insights - Alstom has been awarded a contract worth approximately 380 million euros (437 million dollars) to upgrade the Skyway automated people mover system at George Bush Intercontinental Airport (IAH) in Houston, Texas, and to provide operations and maintenance services for 15 years [1][7]. Group 1: Contract Details - The contract includes the construction of a new Operations Control Center, upgrades to Automatic Train Control and communication systems, and the deployment of 16 new Innovia APM R vehicles [1][8]. - The upgraded Skyway system aims to reduce service disruptions, improve passenger flow between terminals, and enhance the overall travel experience for the record-breaking 48 million passengers that used the airport last year [2][4]. Group 2: Operational Performance - Alstom demonstrated strong operational performance with a 99.63% availability rate for the current system in 2024, indicating reliability amid the airport's major expansion program [3][4]. - A dedicated 48-person operations and maintenance team will be on-site to support the system's reliability during the upgrades [7][8]. Group 3: Industry Position - Alstom is recognized as a market leader in rail services, with over 25 active operations and maintenance projects worldwide, providing a broad portfolio of services solutions [5][9]. - The company has a long-standing partnership with IAH, having operated and maintained the Skyway APM for two decades, reinforcing its role as a trusted mobility partner [4][6].

Core Viewpoint - Genenta Science S.p.A. is transitioning to Saentra Forge, focusing on selective acquisitions in strategic sectors such as biotech, defense, aerospace, and national security technologies [1][3] Company Strategy - The company aims to become an industrial aggregator in sensitive sectors, providing capital and structure to promising scale-ups, thereby enhancing national security and retaining technological value within Italy [3] - Genenta is actively exploring collaboration opportunities for its biotechnology platform, particularly for Temferon, despite not currently being in discussions with strategic partners [1][2] Leadership and Shareholder Commitment - The CEO, Pierluigi Paracchi, has not sold shares in Genenta and has increased his position, emphasizing the commitment of founder-scientists to the company and their opposition to selling shares until Temferon receives third-party validation [2] - The strategic evolution of the company is intended to serve the best interests of shareholders, focusing on long-term value creation through disciplined execution and selective acquisitions [3]

Core Insights - Mission Trail Capital Management has acquired 80,659 shares of Sidetrade, representing 5.39% of the company's outstanding share capital, making it the second US-based investment firm to significantly increase its stake in Sidetrade within three months [1] - Sidetrade is recognized as a leader in the Gartner Magic Quadrant for Invoice-to-Cash Applications for three consecutive years, highlighting its strong market position and innovative technology [14] Company Overview - Sidetrade operates an AI-native Order-to-Cash platform that automates financial processes for large enterprises, utilizing its proprietary Data Lake containing over $8 trillion in B2B payment transactions [4] - The company employs 450 people and supports businesses in 85 countries, indicating a broad international presence [17] Financial Performance - In 2025, Sidetrade reported revenue of €61.4 million, reflecting a 14% increase at constant currency, with subscription revenue at €53.5 million, up 20% and accounting for 87% of total revenue [7] - North America is now Sidetrade's largest market, contributing 30% of group revenue subscriptions and growing at 25% at constant currency [8] - The operating margin exceeded 15% in 2024, with net income rising by 40% to €7.9 million [9] Strategic Developments - Sidetrade transitioned from predictive AI to autonomous execution in 2025, launching the first AI Cash Collection Agent capable of managing collections without human intervention, with 24 agents set to enter live production by the end of Q1 2026 [6] - The company's billing model is based on transaction volume rather than per-user fees, mitigating risks associated with AI-driven pricing pressures [5][10] Management and Investor Sentiment - CEO and Founder Olivier Novasque holds 35% of outstanding shares, aligning management interests with those of shareholders [11] - Analyst consensus is unanimously positive, with target prices suggesting over 100% upside potential [13]

Core Viewpoint - Elis has conducted a share buyback program from March 16 to March 20, 2026, in accordance with EU regulations, aimed at covering employee share plans and obligations related to convertible bonds [2][3]. Summary by Category Share Buyback Details - Total shares purchased during the buyback period amounted to 495,042 shares, with a weighted average price of €25.2081 [3]. - The buyback included transactions on various platforms, including XPAR, DXE, TQE, and AQE, with daily volumes and prices varying across the days [2]. Purpose of Share Buybacks - The primary purposes of the share buyback operations are: 1. To cover maturing performance share plans and allocate free shares to employees as part of the "Elis for All 2026" international employee shareholding plan. 2. To fulfill obligations related to the delivery of treasury shares under the potential conversion of Bonds Convertible into New Shares and/or Exchangeable for Existing Shares (OCEANEs) due September 22, 2029. 3. Any remaining shares are intended to be canceled in accordance with the resolution from the Combined General Meeting held on May 22, 2025 [3].

Core Viewpoint - Harvia Plc has conducted a directed share issue to key employees as part of its share-based incentive program for the performance period 2023–2025, transferring 13,823 own shares without consideration [1][2]. Group 1: Share Issuance Details - The share issue involves the transfer of 13,823 own shares held by the company to key employees participating in the incentive program [2]. - After the transfer, the company retains a total of 6,977 own shares [2]. - The decision for the share transfer is based on the authorization from the Annual General Meeting held on 8 April 2025, and it does not dilute existing shareholdings as the shares are already owned by the company [3]. Group 2: Incentive Program Objectives - The long-term incentive program aims to support the company's strategy, align management objectives with shareholder interests, enhance company value, and strengthen management commitment [4]. Group 3: Company Overview - Harvia is a leading company in the global sauna market, recognized for its well-known brands and comprehensive product portfolio catering to both private and professional customers [5]. - In 2025, Harvia's revenue reached EUR 198.9 million, and the company employs over 700 professionals across various countries including Finland, the United States, Germany, Romania, China, Hong Kong, Austria, Italy, and Sweden [6].

Core Insights - Xiongan New Area is transforming into a modern urban model, driven by the orderly relocation of Beijing's non-capital functions, emphasizing human-centered achievements through significant investments and policy integration [1][6] Investment and Economic Growth - Over the 14th Five-Year Plan period, Xiongan completed cumulative investments exceeding 1 trillion yuan ($145.5 billion) and achieved an average annual GDP growth of 17.1% [6] - The area has developed nearly 215 square kilometers and constructed more than 5,300 buildings [6] Relocation and Integration - The relocation of central enterprises, such as China Huaneng Group, is a core driver, with over 1,000 employees already integrated into daily operations in Xiongan since October 2025 [8] - Targeted policy guarantees ensure that relocated personnel enjoy living and income conditions comparable to those in Beijing, supported by 278 specific integration measures [9] Education and Community Development - The Xiongan campus of Beijing No. 4 High School exemplifies the educational support project, providing high-quality education resources and prioritizing children from relocated families [10][11] - The campus opened in August 2023 and has seen steady enrollment growth, ensuring that relocated households can access familiar educational opportunities [11] Innovation and Technological Development - National policy directs Xiongan to integrate sci-tech and industrial innovation, with the development of the Xiongan New Area Zhongguancun Science Park [12] - Key milestones in 2026 include the release of the Jishu data model and the establishment of trusted data spaces across various sectors, positioning Xiongan as a vital node in the Beijing-Tianjin-Hebei sci-tech innovation hub [13][14]

Core Viewpoint - Pharming Group N.V. has received approval from Japan's Ministry of Health, Labour and Welfare for Joenja® (leniolisib), marking it as the first treatment for activated PI3K delta syndrome (APDS) in Japan and globally for children aged 4 to 11 [1][2][7] Company Overview - Pharming Group N.V. is a global biopharmaceutical company focused on developing and commercializing innovative medicines for rare and life-threatening diseases, headquartered in Leiden, the Netherlands [11] Product Details - Joenja® (leniolisib) is an oral, selective PI3K delta inhibitor approved for patients aged 4 years and older, targeting APDS, a rare primary immunodeficiency [1][9] - The approval is based on positive Phase III clinical trial data demonstrating significant improvements in immune function and tolerability [4][9] Market and Distribution - OrphanPacific, Inc. will act as the Marketing Authorization Holder for Joenja in Japan, collaborating with Pharming for supply and distribution [2] - The launch of Joenja is contingent upon agreement with the MHLW regarding its National Health Insurance drug price [2] Clinical Significance - The approval of Joenja is a significant advancement for the APDS community in Japan, providing the first targeted treatment option for this rare disease [3][4] - The clinical trials included a global, randomized, placebo-controlled study and a Japanese open-label study, both showing improvements in lymphadenopathy and B cell function [4][5] Regulatory Pathway - The application for Joenja was evaluated under the Priority Review pathway after receiving Orphan Drug Designation from the MHLW in May 2023 [5]

Core Insights - Sanofi and Regeneron's Dupixent has been approved in Japan as the first targeted treatment for adults with moderate-to-severe bullous pemphigoid (BP) [1][2] Group 1: Approval and Study Data - The approval is based on the LIBERTY-BP-ADEPT phase 2/3 study, which showed that 18% of patients on Dupixent achieved sustained disease remission compared to 4% on placebo, with a p-value of 0.0250 [2][5] - The study involved 106 adults, with patients receiving Dupixent 300 mg or placebo every two weeks, alongside standard-of-care oral corticosteroids [5][6] Group 2: Treatment Efficacy and Safety - Dupixent patients experienced treatment-related adverse events (AEs) at a rate of 26%, compared to 15% in the placebo group, with conjunctivitis being the most common AE at 4% [3][6] - Sustained disease remission was defined as complete clinical remission with successful tapering of oral corticosteroids by Week 16 without relapse during the 36-week treatment period [6] Group 3: Background on Bullous Pemphigoid - BP is a rare skin disease primarily affecting elderly patients, characterized by intense itching, painful blisters, and lesions, leading to increased infection risk and impaired daily functioning [4][6] - Current treatment options for BP are limited and often involve immunosuppressive therapies, which can exacerbate the disease burden [4] Group 4: Dupixent Overview - Dupixent is a fully human monoclonal antibody that inhibits interleukin-4 (IL4) and interleukin-13 (IL13) signaling pathways, and is not classified as an immunosuppressant [9][10] - It is now available in Japan as a 300 mg pre-filled syringe or pen for subcutaneous injection, with over 1.4 million patients treated globally across various indications [7][10] Group 5: Development and Future Prospects - Dupilumab is being jointly developed by Sanofi and Regeneron, with ongoing studies exploring its efficacy in other diseases driven by type 2 inflammation [11][12] - The approval of Dupixent for BP marks the seventh indication for the drug in Japan, highlighting its expanding therapeutic potential [7][10]